Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. closed $2.35 short of its 52-week high ($24.27), which the company reached on November 8th.
Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer
Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.
Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...
Reuters14h
United States
U.S. President-elect Donald Trump will not go to jail or face any other punishment for his criminal conviction stemming from hush money paid to a porn star, a judge ruled on Friday but said Trump ...
Rugbypass22h
Rugby News
Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...